Skip to main content
Premium Trial:

Request an Annual Quote

Protelica Wins $500K NSF Bioinformatics Grant

NEW YORK (GenomeWeb News) — The National Science Foundation has given Protelica a $500,000 grant to continue developing its DNA mutagenesis technologies in a bioinformatics-based project aimed at developing protein therapies, the company said today.

Protelica will use the two-year, Phase II Small Business Innovation Research funding to develop "a bioinformatics-based understanding of nature’s evolutionary rules, and utilizes Protelica's proprietary DNA mutagenesis technologies to develop small, specific and potent protein blockers," the company said.

This grant is part of a project that began two years ago called "Bioinformatics knowledge-based, universal library design for a non-immunoglobulin, protein-scaffold," according to the Hayward, Calif.-based company.

Protelica CEO and CSO Roberto Crea said in a statement that the firm expects the project to lead to the discovery and development of "new protein therapeutics that may replace the first generation monoclonal antibody drugs."

Filed under

The Scan

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.